Solvonis Therapeutics plc (GB:SVNS)
LSE:SVNS
Want to see GB:SVNS full AI Analyst Report?
SVNS Stock Chart & Stats
0.35 p
--
Market closed
0.35 p
--
Day’s Range― - ―
52-Week Range0.13 p - 0.40 p
Previous CloseN/A
VolumeN/A
Average Volume (3M)34.43M
Market Cap
£17.02M
Enterprise Value16.26M
Total Cash (Recent Filing)£757.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,806,403,300
10 Day Avg. Volume23,401,787
30 Day Avg. Volume34,434,652
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-2.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt in 2024 and generally low leverage reduce solvency risk and lower fixed financing obligations. This durable balance-sheet strength gives management flexibility to pursue financing or strategic options without immediate refinancing pressure, a structural buffer versus leveraged peers.
Improving Cash Flow TrendFree cash flow improvement year-over-year signals initial cost controls or operational efficiency gains. If sustained, this structural improvement can lengthen runway, reduce future external funding needs, and support a transition toward self-funded operations over the medium term.
Lean Cost BaseA three-person workforce implies an extremely lean operating model with low fixed personnel costs. Structurally low headcount can materially extend cash runway, allow rapid reallocation of resources, and provide flexibility while management seeks a viable revenue model or strategic partner.
Bears Say
Zero RevenueRevenue dropping to zero in 2024 removes the company's operating income base and eliminates margin generation. Without recurring sales, the business lacks customer validation and predictable cash inflows, making medium-term viability contingent on restoring sustainable revenue sources.
Persistent Losses And Cash BurnOngoing operating and net losses with materially negative operating cash flow demonstrate continued capital consumption. This pattern forces dependence on external financing, limits the company's ability to invest in growth or R&D, and raises execution risk if losses persist over multiple quarters.
Eroding Equity BaseDeclining equity and asset bases alongside strongly negative ROE indicate the capital base is being consumed rather than compounded. This structural erosion reduces financial flexibility, increases the likelihood of dilution or distress financing, and constrains strategic choices over time.
Solvonis Therapeutics News
SVNS FAQ
What was Solvonis Therapeutics plc’s price range in the past 12 months?
Solvonis Therapeutics plc lowest share price was 0.13 p and its highest was 0.40 p in the past 12 months.
What is Solvonis Therapeutics plc’s market cap?
Solvonis Therapeutics plc’s market cap is £17.02M.
When is Solvonis Therapeutics plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Solvonis Therapeutics plc’s earnings last quarter?
Currently, no data Available
Is Solvonis Therapeutics plc overvalued?
According to Wall Street analysts Solvonis Therapeutics plc’s price is currently Overvalued.
Does Solvonis Therapeutics plc pay dividends?
Solvonis Therapeutics plc does not currently pay dividends.
What is Solvonis Therapeutics plc’s EPS estimate?
Solvonis Therapeutics plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics plc have?
Solvonis Therapeutics plc has 6,806,403,300 shares outstanding.
What happened to Solvonis Therapeutics plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Solvonis Therapeutics plc?
Currently, no hedge funds are holding shares in GB:SVNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics plc
Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous polymer-carriers for use in liquid chemicals. It also provides GRAFTAMID, a line of high-temperature elastomers based on nanostructured polyolefin-polyamide alloys for high-tech hardening modifiers in polyamide compounds, as well as use as an independent compound in hot melt adhesives; and GRAFTAKIT, a reactive liquid or solid super-concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds. In addition, the company offers GRAFTALLOY, a line of polymer-polymer nano-alloys to increase abrasion and temperature resistance, and impact strength, as well as reduce friction coefficient; GRAFTASYNT, a line of synthetic products comprising halogen-free flame retardants; and GRAFTAMER, a thermo-reversible crosslinking, self-hardening, and self-healing smart polymer with shape memory, etc. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Technical Analysis
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―
Options Prices
Currently, No data available
---